Who makes MR-130A-01 Transdermal patch?

MR-130A-01 Transdermal patch is developed by Mylan Pharmaceuticals Inc.

What development phase is MR-130A-01 Transdermal patch in?

MR-130A-01 Transdermal patch is in Phase 2.

Last reviewed 2026-04-19 · How we verify

MR-130A-01 Transdermal patch

Mylan Pharmaceuticals Inc · Phase 2 active Small molecule

At a glance

Generic name	MR-130A-01 Transdermal patch
Sponsor	Mylan Pharmaceuticals Inc
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential (PHASE3)
Investigating Ovulation Inhibition for Use as a Contraceptive (PHASE2)
Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MR-130A-01 Transdermal patch CI brief — competitive landscape report
MR-130A-01 Transdermal patch updates RSS · CI watch RSS
Mylan Pharmaceuticals Inc portfolio CI